Development of a UV visible spectrophotometric method for simultaneous estimation of Ranolazine and Metoprolol
Abstract
Ranolazine being Na+ channel blocker agent, decreases the chances of angina attacks. Metoprolol exerts specific β1 blocking effect which results into decreased cardiac contractility and heart Rate (1). Ultimately reduces oxygen demand of heart. Metoprolol enhances the pharmacological activity of Ranolazine so the combination gives better therapeutic activity (2).
There is no UV visible method present for the simultaneous estimation of Ranolazine and Metoprolol. To formulate and evaluate such a formulation involving mentioned drugs this simultaneous equation method was developed using 0.1 N HCl as a solvent. Chosen wavelengths were 272 nm and 242 nm for Ranolazine and Metoprolol Succinate respectively. Linearity range was seen to be 7.5 to 40 ppm for Ranolazine and 1 to 5 ppm for Metoprolol. Recovery studies and Validation were successfully performed according to ICH guidelines. This method can be applied for any formulation consisting mentioned drugs without interference of other excipients.
Keywords: UV visible spectrophotometry, Simultaneous estimation, Ranolazine, Metoprolol succinate, Analytical Method development, Angina Pectoris
Downloads
References
2. Tavazzi L: Ranolazine, a new antianginal drug. Future Cardiol. 2005; 1(4):447-455. https://doi.org/10.2217/14796678.1.4.447
3. Sossalla S, Maier LS. Role of Ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol. Ther. 2012; 133(3):311-323. https://doi.org/10.1016/j.pharmthera.2011.11.003
4. Poornima K, Kp C. Development and Validation of RP-HPLC Method for Estimation of Metoprolol and Ranolazine in Bulk and in Formulation. J. Chron. Ther. Drug Deliv. 2015; 6(2): 41–8.
5. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, et al. Ranolazine combined with Enalapril or Metoprolol prevents progressive LV dysfunction and re-modelling in dogs with moderate heart failure. Am. J. physiol. Heart circ. 2008; 295(5):2149-55 https://doi.org/10.1152/ajpheart.00728.2008
6. Drug profile Ranolazine, https://pubchem.ncbi.nlm.nih.gov/compound/ranolazine.
7. https://www.drugbank.ca/drugs/DB00243.
8. Drug profile Metoprolol succinate, https://pubchem.ncbi.nlm.nih.gov/compound/metoprolol.
9. https://www.drugbank.ca/drugs/DB00264.
10. ICH guidelines for analytical method validation
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_ R1/Step4/Q2_R1 Guideline.pdf.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.